Bupropion

IntelGenx to Initiate Phase 1 Trial of Montelukast

Edit Stockhouse 13 Jul 2016

mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. The objectives of the trial are to demonstrate. 1 ... IntelGenx is collaborating with Dr ... One of these mechanisms, leukotriene signaling, is related to asthma. In consequence, Dr ... Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder.  ... ....

IntelGenx to Initiate Phase 1 Trial of Montelukast (IntelGenx Technologies Corp)

Edit Public Technologies 13 Jul 2016

(Source. IntelGenx Technologies Corp) ... mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. The objectives of the trial are to demonstrate. 1 ... montelukast when delivered using IntelGenx oral film crosses the blood brain barrier ... Dr ... Horst G ... Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder....

IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction

Edit Stockhouse 11 Jul 2016

IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction. SAINT-LAURENT, QUEBEC--(Marketwired - July 11, 2016) - IntelGenx Corp ... and IntelGenx Corp ... The ruling in the U.S ... Patent No ... Patent No ... Dr ... Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder.  ... ....

IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction (IntelGenx Technologies Corp)

Edit Public Technologies 11 Jul 2016

(Source. IntelGenx Technologies Corp). SAINT-LAURENT, QUEBEC -- (Marketwired) -- 07/11/16 -- IntelGenx Corp ... and IntelGenx Corp. to the United States Court of Appeals for the Federal Circuit from the final judgment issued by the U.S ... The ruling in the U.S ... Patent No ... Dr ... Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder ... 217)....

IntelGenx and RedHill Biopharma Announce Signing of Definitive Agreement for Commercialization of RIZAPORT(TM) with Grupo Juste for Spain and Additional Potential Territories (IntelGenx Technologies Corp)

Edit Public Technologies 05 Jul 2016

(Source. IntelGenx Technologies Corp). SAINT-LAURENT, QUEBEC -- (Marketwired) -- 07/05/16 -- IntelGenx Corp., (TSX VENTURE.IGX)(OTCQX.IGXT), and RedHill Biopharma Ltd ... Full details of the financial terms of the agreement were not disclosed ... Horst G ... About RIZAPORT. ... Forfivo XL, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder ... Source....

Everything you need to know about quitting smoking (Parkland Health & Hospital System - Dallas County Hospital District)

Edit Public Technologies 20 Jun 2016

(Source. Parkland Health & Hospital System - Dallas County Hospital District). Posted. 6/20/2016. Parkland's Smoking Cessation Clinic can help you quit smoking ... So, if you don't smoke or use tobacco products, don't start! ... After 5 to 15 years, the risk of stroke is the same as a person who never smoked. Tobacco dependence ... patch, gum, lozenges, mini-lozenges, inhalers, intranasal spray Varenicline(Chantix) Bupropion( Wellbutrin/Zyban)....

Pharmacological Treatments for Obesity and Weight Loss (American College of Cardiology Foundation)

Edit Public Technologies 15 Jun 2016

The drugs were orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide ... Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were associated with the highest odds of adverse event-related treatment discontinuation....

Revealed... the 5 weight loss drugs that ACTUALLY work - helping obese people shed up ...

Edit The Daily Mail 14 Jun 2016

Scientists at the University of California found of the drugs - orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide - the last two, marketed as Qsymia, Saxenda and Victoza were most effective ... ....

Study compares effectiveness of weight-loss drugs

Edit Science Daily 14 Jun 2016

In an analysis that included nearly 30,000 overweight or obese adults, compared with placebo, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were each associated with achieving at least 5 percent weight loss at 52 weeks, and phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss, according to a study ... ....

Experts rated weight-loss drugs and Qsymia came out on top

Edit The Oklahoman 14 Jun 2016

In the diet-medication sweepstakes, we have a winner ... Over the past four years, the FDA has, with great deliberation, approved four new drugs for weight loss ... Half of the recruits had a BMI greater than 36.1 — well into the obese range — and half had a lower BMI ... Contrave — a drug that combines the antidepressant bupropion and the anti-addiction drug naltrexone — may risk complications for patients with substance addiction issues ... ———....

What Does It Take To Get A Drug Banned For Enhancing Athletes' Performance?

Edit National Public Radio 14 Jun 2016

i. Russia's Maria Sharapova appealed a two-year suspension for taking the banned drug meldonium. William West/AFP/Getty Images hide caption. toggle caption William West/AFP/Getty Images. Russia's Maria Sharapova appealed a two-year suspension for taking the banned drug meldonium. William West/AFP/Getty Images ... The is public and currently includes drugs ranging from antidepressant bupropion to telmisartan, a blood pressure medication ... i ... ....

Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation (Orexigen Therapeutics Inc)

Edit Public Technologies 08 Jun 2016

In its application, Actavis seeks to market and sell a generic version of the currently approved dose of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets prior to the expiration of U.S ... About CONTRAVE (naltrexone HCl / bupropion HCl extended release) ... naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine....

Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO (Orexigen Therapeutics Inc)

Edit Public Technologies 08 Jun 2016

commercialization of Contrave(naltrexone HCl / bupropion HCl extended release) and Mysimba, as the drug is known in Europe ... About CONTRAVE (naltrexone HCl / bupropion HCl extended release) ... naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine ... Neuropsychiatric Reactions in Patients Taking Bupropion for Smoking Cessation....